Literature DB >> 10532247

The effects of SERMs on the skeleton.

J H Tobias1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10532247     DOI： 10.1007/BF03343617

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  24 in total

1.  Raloxifene and estrogen: comparative bone-remodeling kinetics.

Authors:  R P Heaney; M W Draper
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

2.  A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.

Authors:  M W Draper; D E Flowers; W J Huster; J A Neild; K D Harper; C Arnaud
Journal:  J Bone Miner Res       Date:  1996-06       Impact factor: 6.741

3.  Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.

Authors:  M B Marttunen; P Hietanen; A Tiitinen; O Ylikorkala
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

4.  Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.

Authors:  H Z Ke; H A Simmons; C M Pirie; D T Crawford; D D Thompson
Journal:  Endocrinology       Date:  1995-06       Impact factor: 4.736

5.  Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.

Authors:  E G Lufkin; M D Whitaker; T Nickelsen; R Argueta; R H Caplan; R K Knickerbocker; B L Riggs
Journal:  J Bone Miner Res       Date:  1998-11       Impact factor: 6.741

6.  Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.

Authors:  M E Nuttall; J N Bradbeer; G B Stroup; D P Nadeau; S J Hoffman; H Zhao; S Rehm; M Gowen
Journal:  Endocrinology       Date:  1998-12       Impact factor: 4.736

7.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

8.  Treatment of postmenopausal osteoporosis with transdermal estrogen.

Authors:  E G Lufkin; H W Wahner; W M O'Fallon; S F Hodgson; M A Kotowicz; A W Lane; H L Judd; R H Caplan; B L Riggs
Journal:  Ann Intern Med       Date:  1992-07-01       Impact factor: 25.391

9.  The effects of raloxifene on tibia histomorphometry in ovariectomized rats.

Authors:  G Evans; H U Bryant; D Magee; M Sato; R T Turner
Journal:  Endocrinology       Date:  1994-05       Impact factor: 4.736

10.  Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study.

Authors:  C Hassager; A Colwell; A M Assiri; R Eastell; R G Russell; C Christiansen
Journal:  Clin Endocrinol (Oxf)       Date:  1992-07       Impact factor: 3.478
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.